SHAL TECHNOLOGIES, INC.

Biotech · Private

SH7139, a selective ligand targeting HLA-DR10 for non-Hodgkin's lymphoma treatment

Grants
$835K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma$740,587
Federal grantDepartment of Health and Human Services · Phase II · A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma$94,422
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2202PEPTIFORGE, INC——
2203BIOPROCESSING INNOVATIVE COMPANY INC——
2204ArCHitect Therapeutics——
2205SHAL TECHNOLOGIES, INC.——
2206Cognosetta, Inc.——
2207RJS Biologics L.L.C.——
2208TRAVERSE BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Selective High Affinity Ligand Diagnostics And Therapeuticsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.